Icon Plc (NASDAQ:ICLR – Get Free Report) Director Ciaran Murray sold 10,000 shares of the business’s stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $200.18, for a total transaction of $2,001,800.00. Following the completion of the sale, the director owned 7,000 shares in the company, valued at approximately $1,401,260. This trade represents a 58.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Ciaran Murray also recently made the following trade(s):
- On Monday, November 2nd, Ciaran Murray sold 3,452 shares of Icon stock. The shares were sold at an average price of $205.66, for a total transaction of $709,938.32.
Icon Price Performance
Shares of NASDAQ:ICLR traded down $3.25 during trading hours on Monday, hitting $191.40. 826,218 shares of the company’s stock traded hands, compared to its average volume of 1,253,686. Icon Plc has a 52 week low of $66.57 and a 52 week high of $219.04. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.32 and a current ratio of 1.32. The company’s fifty day simple moving average is $179.01 and its two-hundred day simple moving average is $147.43. The company has a market cap of $14.65 billion, a price-to-earnings ratio of 32.94, a price-to-earnings-growth ratio of 10.78 and a beta of 1.19.
Icon (NASDAQ:ICLR – Get Free Report) last released its earnings results on Tuesday, October 27th. The medical research company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.62 by $0.04. Icon had a net margin of 5.45% and a return on equity of 7.73%. The business had revenue of $2.02 billion for the quarter, compared to the consensus estimate of $2.01 billion. During the same period in the previous year, the firm earned $3.31 EPS. The business’s revenue for the quarter was down .9% on a year-over-year basis. As a group, equities analysts anticipate that Icon Plc will post 9.71 EPS for the current fiscal year.
Institutional Investors Weigh In On Icon
Several hedge funds have recently made changes to their positions in ICLR. Pathstone Holdings LLC grew its holdings in shares of Icon by 15.5% during the third quarter. Pathstone Holdings LLC now owns 29,193 shares of the medical research company’s stock valued at $4,962,000 after buying an additional 3,927 shares in the last quarter. First Trust Advisors LP raised its position in Icon by 330.5% during the third quarter. First Trust Advisors LP now owns 8,654 shares of the medical research company’s stock valued at $1,471,000 after buying an additional 6,644 shares during the period. Heartland Advisors Inc. raised its position in Icon by 17.7% during the third quarter. Heartland Advisors Inc. now owns 53,974 shares of the medical research company’s stock valued at $9,175,000 after buying an additional 8,131 shares during the period. Stephens Investment Management Group LLC lifted its stake in Icon by 7.1% in the 3rd quarter. Stephens Investment Management Group LLC now owns 771,246 shares of the medical research company’s stock worth $131,104,000 after acquiring an additional 50,985 shares in the last quarter. Finally, Muhlenkamp & Co. Inc. boosted its position in Icon by 1.1% during the 3rd quarter. Muhlenkamp & Co. Inc. now owns 67,038 shares of the medical research company’s stock worth $11,396,000 after acquiring an additional 701 shares during the period. Hedge funds and other institutional investors own 95.61% of the company’s stock.
Analyst Ratings Changes
ICLR has been the topic of several research reports. Robert W. Baird upped their price target on Icon from $210.00 to $249.00 and gave the company an “outperform” rating in a report on Thursday, October 29th. BMO Capital Markets restated an “outperform” rating and issued a $235.00 target price on shares of Icon in a report on Thursday, October 29th. Truist Financial boosted their target price on Icon from $209.00 to $268.00 and gave the stock a “buy” rating in a research report on Thursday, October 29th. UBS Group upped their target price on Icon from $195.00 to $236.00 and gave the company a “neutral” rating in a report on Thursday, October 29th. Finally, Bank of America upgraded Icon from an “underperform” rating to a “neutral” rating and set a $185.00 price target for the company in a research report on Friday, October 9th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $213.76.
View Our Latest Analysis on ICLR
Icon Company Profile
ICON plc is a global contract research organization (CRO) that provides outsourced development services to pharmaceutical, biotechnology, medical device and government organizations. Its work supports the development of medicines and other healthcare products from early research through clinical trials and regulatory submission. The company’s services include clinical trial design and management, data management and biostatistics, regulatory support, laboratory services, medical imaging and patient recruitment.
See Also
- Five stocks we like better than Icon
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.
